FindTrial
Sign In

STUDYING THE ADVANTAGE OF ADDITIONAL USE OF VITAMIN SUPPLEMENTS (VITAMIN B1 AND VITAMIN C) IN CHILDREN WITH SEVERE DENGUE GETTING ADMITTED IN PEDIATRIC INTENSIVE CARE UNIT.

CLINICAL EFFECTIVENESS OF ASCORBIC ACID AND THIAMINE AS ADJUNCTIVE THERAPY IN CHILDREN WITH SEVERE DENGUE REQUIRING PICU (PEDIATRIC INTENSIVE CARE UNIT) CARE- OPEN LABELLED RANDOMISED CONTROLLED TRIAL.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021244
Enrollment
66
Registered
2019-09-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A90- Dengue fever [classical dengue]

Interventions

Intervention1: GroupA- Ascorbic acid and Thiamine Group B- Nil: Group A will receive Ascorbic acid and Thiamine intravenously diluted in 10 ml NS given as separate infusions over 30 min for 3 days. As

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children with severe dengue (as per WHO 2009 criteria) with confirmed dengue serology.

Exclusion criteria

Exclusion criteria: Children 1.Those who have been on steroids >2 weeks during admission. 2.With pre-existing liver/renal/hematological/cardiac disease. 3.Whose parents refuse consent.

Design outcomes

Primary

MeasureTime frame
1.Duration of intravenous fluid therapy(hours) 2.Duration of PICU stay(hours) 3.Duration of hospital stay(hours) 4.% MortalityTimepoint: All parameters are measured at end point- discharge/death—

Secondary

MeasureTime frame
MACROCIRCULATION ASSESSMENT 1.Estimated creatinine clearance 2.Stroke volume index DESCRIPTIVE SCORING 3.PELODS score PROGNOSTIC SCORING 4.PRISM3 score 5.VIS score MICROCIRCULATION ASSESSMENT 6.Lactate clearance 7.â?²1pH,â?²2pH,â?²3pH 8.Ferritin level REQUIREMENT(YES/NO) 9.Ventilator requirement(YES/NO) 10.Non invasive ventilation requirement(YES/NO) 11.Oxygen requirement(YES/NO) 12.Extracorporeal therapy/Continuous Veno-venous hemodiafiltration(CVVHDF) requirement(YES/NO).Timepoint: Assessed every 24 hours for 3 days—

Countries

India

Contacts

Public ContactSASIDARAN K

MEHTA MULTISPECIALITY HOSPITALS PVT. LTD

sasidarpgi@gmail.com9597844134

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026